CSBio CSBio

X
[{"orgOrder":0,"company":"Redx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Redx Pharma nominates RXC007, a novel, orally active ROCK2 inhibitor as next drug development candidate in fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Redx Pharma"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$377.0 million","upfrontCash":"Undisclosed","newsHeadline":"Redx Signs Out Licensing Agreement With Astrazeneca","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Redx Pharma"},{"orgOrder":0,"company":"Nuformix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuformix Reports Results from Pre-clinical Pilot Study in IPF for NXP004 Programme","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nuformix"},{"orgOrder":0,"company":"DJS Antibodies","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$255.0 million","newsHeadline":"AbbVie Acquires DJS Antibodies, Further Strengthening Immunology Pipeline","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"DJS Antibodies"},{"orgOrder":0,"company":"C4X Discovery","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$402.0 million","upfrontCash":"$2.0 million","newsHeadline":"C4XD Agreement with AstraZeneca","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"C4X Discovery"},{"orgOrder":0,"company":"Istesso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Istesso Announces FDA Fast Track and Orphan Drug Designation for MBS2320","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Istesso"},{"orgOrder":0,"company":"Senisca","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"SENISCA Awarded Innovate UK Grant to Develop Oligonucleotide Therapeutics for The Treatment of Idiopathic Pulmonary Fibrosis (IPF).","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Senisca"}]

Find Drugs for Pulmonary/Respiratory Diseases in Preclinical Development in UNITED KINGDOM

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The funding will be used towards the development of Oligonucleotide-based Thearpies for the treatment of idiopathic pulmonary fibrosis (IPF), using SENISCA’s proprietary technology, harnessing RNA biology to rejuvenate aged senescent cells.

            Lead Product(s): Oligonucleotide-based Thearpy

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undislcosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Innovate UK

            Deal Size: $0.7 million Upfront Cash: Undisclosed

            Deal Type: Funding April 20, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            MBS2320 is a first-in-class investigational drug which is currently in clinical development for the treatment of rheumatoid arthritis (RA) where it has demonstrated a unique profile, reducing inflammation and supporting the remodelling of damaged bone.

            Lead Product(s): MBS2320

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MBS2320

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 05, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            C4XD signs licence agreement with AstraZeneca for the development and commercialisation of NRF2 Activator programme. NRF2 is an important natural regulator, controlling the expression of antioxidant genes, and it plays a key role in cellular defense against external insults.

            Lead Product(s): C4X_6665

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: C4X_6665

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: AstraZeneca

            Deal Size: $402.0 million Upfront Cash: $2.0 million

            Deal Type: Agreement November 28, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, AbbVie will pay DJS. DJS shareholders remain eligible for potential additional payments upon the achievement of certain development milestones related to the success of the DJS-002 program.

            Lead Product(s): DJS-002

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: DJS-002

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: AbbVie Inc

            Deal Size: Undisclosed Upfront Cash: $255.0 million

            Deal Type: Acquisition October 20, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            NXP004 showed a dose-dependent reduction in the secretion of several key ECM components.These data suggest NXP004 compares favourably to current standard of care with regard to anti-fibrotic activity in this model.

            Lead Product(s): NXP004

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NXP004

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 19, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the exclusive global agreement, AstraZeneca will take RXC006 forward into clinical development, targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF).

            Lead Product(s): RXC006

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RXC006

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: AstraZeneca

            Deal Size: $377.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement August 04, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Preclinical data with compounds from Redx’s ROCK2 programme have demonstrated robust anti-fibrotic effects in a range of industry-standard in vivo models.

            Lead Product(s): RXC007

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 09, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY